Compare PRE & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRE | ACRS |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | Hong Kong | United States |
| Employees | 98 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.6M | 311.0M |
| IPO Year | N/A | 2015 |
| Metric | PRE | ACRS |
|---|---|---|
| Price | $21.26 | $4.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $30.50 | $10.20 |
| AVG Volume (30 Days) | 299.1K | ★ 1.1M |
| Earning Date | 06-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $108.69 | N/A |
| Revenue Next Year | $58.68 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.01 | $1.34 |
| 52 Week High | $23.63 | $5.15 |
| Indicator | PRE | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 51.61 |
| Support Level | $12.92 | $4.15 |
| Resistance Level | $21.72 | $4.73 |
| Average True Range (ATR) | 1.86 | 0.24 |
| MACD | 0.17 | -0.03 |
| Stochastic Oscillator | 77.81 | 60.48 |
Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.